One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

Kei Takayama; Hiroki Kaneko; Tadasu Sugita; Ruka Maruko; Kyoko Hattori; Eimei Ra; Kenichi Kawano; Keiko Kataoka; Yasuki Ito; Hiroko Terasaki

doi:10.1159/000461785

One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

Kei Takayama, Hiroki Kaneko, Tadasu Sugita, Ruka Maruko, Kyoko Hattori, Eimei Ra, Kenichi Kawano, Keiko Kataoka, Yasuki Ito, Hiroko Terasaki

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.

Original language	English
Pages (from-to)	105-110
Number of pages	6
Journal	Ophthalmologica
Volume	237
Issue number	2
DOIs	https://doi.org/10.1159/000461785
Publication status	Published - 01-03-2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Ophthalmology
Sensory Systems

Access to Document

10.1159/000461785

Cite this

@article{f4be1694e8e34408a6da034f86c98947,

title = "One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration",

abstract = "Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with na{\"i}ve AMD received 3 + PRN IAI treatment and 47 eyes with na{\"i}ve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.",

author = "Kei Takayama and Hiroki Kaneko and Tadasu Sugita and Ruka Maruko and Kyoko Hattori and Eimei Ra and Kenichi Kawano and Keiko Kataoka and Yasuki Ito and Hiroko Terasaki",

note = "Publisher Copyright: {\textcopyright} 2017 S. Karger AG, Basel.",

year = "2017",

month = mar,

day = "1",

doi = "10.1159/000461785",

language = "English",

volume = "237",

pages = "105--110",

journal = "Ophthalmologica",

issn = "0030-3755",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

AU - Takayama, Kei

AU - Kaneko, Hiroki

AU - Sugita, Tadasu

AU - Maruko, Ruka

AU - Hattori, Kyoko

AU - Ra, Eimei

AU - Kawano, Kenichi

AU - Kataoka, Keiko

AU - Ito, Yasuki

AU - Terasaki, Hiroko

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.

AB - Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.

UR - https://www.scopus.com/pages/publications/85014122012

UR - https://www.scopus.com/inward/citedby.url?scp=85014122012&partnerID=8YFLogxK

U2 - 10.1159/000461785

DO - 10.1159/000461785

M3 - Article

C2 - 28231566

AN - SCOPUS:85014122012

SN - 0030-3755

VL - 237

SP - 105

EP - 110

JO - Ophthalmologica

JF - Ophthalmologica

IS - 2

ER -

One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this